New treatments
From multiple pills per day to one treatment per month: progress in HIV medication made possible by pharma collaborations
Unprecedented collaborations between different pharmaceutical companies have resulted in extraordinary progress for HIV patients over the past four decades. From […] December 5, 2022 · Janssen PharmaceuticaRejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia
Diepenbeek, Belgium, 15 November 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, […] November 15, 2022 · Turnstone CommunicationsIs Belgium becoming a hub for gene therapy?
Ghent, Belgium, 10 November 2022 – Gene therapy provides solutions to deadly diseases. Is the technology ready for a big […] November 10, 2022 · Turnstone CommunicationsIntressa Vascular secures EUR 18 million in financing to support the development of its multilayer Allay™ Aortic Stent for the treatment of aortic dissection
Intressa Vascular is using its proprietary stent braiding technology to develop an innovative multilayer stent for the treatment of aortic […] October 25, 2022 · Turnstone Communications
Gene therapy challenges and the solutions in sight
Dr. Federico Mingozzi is the CSO of Spark Therapeutics, the company behind Luxturna – the world’s first FDA-approved gene therapy […] October 19, 2022 · BioVox
V-Bio Ventures leads Sibylla Biotech's EUR 23 million Series A to advance a novel therapeutic approach for undruggable diseases
Ghent, Belgium, 4 October 2022 – V-Bio Ventures announces the successful close of a EUR 23 million Series A financing […] October 4, 2022 · V-Bio Ventures
From pattern to patient: microbiome research needs to bridge the gap to the clinic
The microbiome has been a trending scientific topic in recent years. Researchers have uncovered correlations between the human microbiome and […] September 7, 2022 · BioVox
The inspiring potential of gene therapy in neurology
Dr. Monica Bennett is Head of Gene Therapy Unit at Novartis, the company behind the world’s only gene therapy approved […] September 7, 2022 · BioVoxV-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain
Ghent, Belgium, 31 August 2022 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain […] August 31, 2022 · V-Bio Ventures
Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease
Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The […] August 17, 2022 · V-Bio Ventures
Gene therapy pioneer Dr. Katherine High on the past and future of the field
Dr. Katherine High is one of gene therapy’s pioneers, who has contributed to a long list of firsts in the […] August 17, 2022 · BioVox
Dualyx: restoring the body’s balance in autoimmune diseases
Belgian start-up Dualyx is developing a novel approach with the potential to treat a wide range of autoimmune disorders. The […] May 12, 2022 · V-Bio Ventures
Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions
Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, appoints […] May 12, 2022 · Turnstone Communications